PRIMARY STUDY
Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice
Key Findings: This review discusses the endocannabinoid system (ECS) and how it affects the pathology of three neurodegenerative disorders: Alzheimer's, Parkinson's, and Multiple Sclerosis. It also discusses the potential therapeutic effects of cannabinoids in these disorders. Pre-clinical data is compelling but more research is needed to confirm the therapeutic indication of cannabis in these conditions.
Type of Study: Meta-analysis
Study Result: Inconclusive
Research Location(s): Brazil
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, PPAR - Gamma, GPCR
Ligands Studied: Dopamine, GABA, Glutamate, Serotonin, Pro-inflammatory cytokines
Citation: Paes-Colli Y, et al. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Front Cell Neurosci. 2022; 16:917164. doi: 10.3389/fncel.2022.917164
Authors: Paes-Colli Y, Aguiar AFL, Isaac AR, Ferreira BK, Campos RMP, Trindade PMP, de Melo Reis RA, Sampaio LS
